In particular, Braun et al. confirmed the association between PBRM1 alterations and the response to Nivolumab in the tissue samples of a validation cohort of patients with metastatic clear cell renal cell carcinoma enrolled in a prospective clinical trial and treated with Nivolumab or Everolimus [63]. Here, PBRM1 is linked to clear cell renal carcinoma.